Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UroSens Receives Funding and Enters into Clinical Trials

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Board of directors strengthened with key appointments.

UroSens Ltd has announced that it has received £0.5M ($0.8M) investment and has entered into clinical trials to assess the accuracy of its novel UroSens Mcm5-ELISA diagnostic test for the detection of bladder cancer.

The funding has been received from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures’ Finance for Business North East Accelerator Fund, and existing investors.

In addition to the £0.5M investment, UroSens has recently been awarded a grant of £250,000 from the Technology Strategy Board.

The new funding will be used to enable UroSens to carry out a series of clinical studies, which will see the Company working with over 1,200 patients at four leading UK hospitals.

The study is expected to be completed by October 2013. UroSens has secured ethics approval to conduct similar trials for the detection of prostate cancer.

With over 40,000 new cases of prostate cancer and 11,000 of bladder cancer each year in the UK, current diagnostic tests are unreliable, resulting in many unnecessary biopsies.

For both diseases, the UroSens Mcm5-ELISA diagnostic test is expected to significantly reduce the number of patients undergoing these invasive and costly procedures because it offers significantly more accurate diagnostic results.

The new test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the technology transfer arm of Cancer Research UK.

The UroSens Mcm5-ELISA test is compatible with established assay technologies and automated platforms and has achieved CE mark as a research use only product, which will allow the product to be commercialized throughout the EU and certain wider markets.

UroSens has also announced two appointments to strengthen its board of directors. Joining the board, effective immediately, are Mr Dean Slagel of Esperante and Dr Alex Buchan of Northstar Ventures.

Dean Slagel has been appointed Non-Executive Director and brings over 20 years of life science industry operational, business development and investing experience.

Alex Buchan has been appointed Board Observer. He joined Northstar in September 2004 following a series of senior commercial roles in the biotechnology sector at companies including Cybersense, Compugen, SDI Europe, EnSys Europe and Archaeus.

Dr Ian Campbell, CEO at UroSens, said: “These are significant steps forward for our company. We are grateful to our existing shareholders, Northstar Ventures and Esperante for the investment. Alongside our successful TSB grant application, this new funding enables us to progress with clinical trials and increase the pace of our commercial development.”

Dr Alex Buchan of Northstar Ventures added: “Bladder cancer is the fifth most common cancer in the UK, with the highest recurrence rate of any malignancy. We are delighted to have invested in UroSens, with its pioneering detection tests and technology, and I look forward to working with the UroSens team.”

Dean Slagel of Esperante commented: “Esperante is delighted to have invested in UroSens, which offers a novel and potentially ground-breaking urological cancer diagnostic being developed under the leadership of an experienced and high calibre management team. We look forward to continuing to support UroSens through to commercialization.”

The Finance for Business North East Accelerator Fund is backed by the European Regional Development Fund and the European Investment Bank.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
Immune-Cell Population Predicts Immunotherapy Response in Melanoma
All patients with high levels of one immune-cell type responded to treatment.
Effects of Chemotherapy on Developing Ovaries in Female Fetuses
Researchers at University of Edinburgh have shown that etoposide can damage the development of the ovaries while a fetus is in the womb.
Breast Tumors Evolve in Response to Hormone Therapy
Researchers have suggested that analyzing a single sample of the breast tumor is insufficient for understanding how a patient should best be treated.
Cutting off the Cancer Fuel Supply
Research from investigators at Rutgers Cancer Institute of New Jersey and Princeton University has identified a new approach to cancer therapy in cutting off a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy. The co-corresponding authors of the work are Rutgers Cancer Institute Deputy Director Eileen P. White, PhD, and researcher ‘Jessie’ Yanxiang Guo, PhD.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
New Tech Joins the Battle Against Hep B
A method for “silencing” RNA that emerged from a University of Wisconsin—Madison spinoff company is in clinical trials in Europe, Asia and the United States against hepatitis B, an infection that can destroy the liver.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!